Optimi completes MDMA batch for Canada trial, Israel study, Australia supply
The Vancouver company said a single production run will support a proposed Canadian Phase 3 PTSD trial, a MAPS-partnered study in Israel, and continued commercial exports to Australia.
Optimi Health Corp. said on October 20, 2026 that it had finished a new production batch of its MDMA (3,4-methylenedioxymethamphetamine) finished drug product.1
The company said the capsules were made at its GMP-compliant facility in Princeton, British Columbia under a Health Canada Drug Establishment Licence, and are meant to cover three separate programs: a proposed Phase 3 MDMA-assisted therapy trial in Canada for PTSD, a further commercial shipment to Australia expected before year end 2026, and a previously disclosed clinical study in Israel run with the Multidisciplinary Association for Psychedelic Studies (MAPS).1
For the Canadian study, Optimi said the trial aims to enroll up to 100 people across several Canadian sites, with a focus on veterans and current or former frontline workers.1 The company said participants would get the company's synthetic MDMA hydrochloride in two dosage forms, taken during two monitored sessions that pair the drug with psychotherapy, spaced weeks apart, followed by post-session assessments.1 The main efficacy measure will be change in the Clinician-Administered PTSD Scale (CAPS-5), described as the standard clinician-rated tool for PTSD severity.1 Optimi said it expects the trial to start in 2027.1
On Australia, the company said it holds import permits for MDMA, with the next shipment planned before the end of 2026 to supply clinics and pharmacies through Optimi Australia.1 It added that Australian clinicians can prescribe MDMA capsules for PTSD under the Therapeutic Goods Administration's Authorised Prescriber Scheme, with coverage from payers including the Department of Veterans' Affairs, the National Disability Insurance Scheme, WorkCover, and Medibank.1
On the Israel program, Optimi said it supplies MDMA capsules for MAPS Israel's Healing October 7th project, which includes a PTSD clinical trial that has received formal approval from the Israeli Ministry of Health.1
The company cautioned that MDMA-assisted therapy's safety and efficacy for PTSD remain under investigation in Canada, and none of its MDMA products have Health Canada market authorization.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.